Sulfonylureas, which stimulate insulin secretion, and metformin, which reduces hepatic gluconeogenesis and improves insulin sensitivity, are widely used to treat patient with T2D due to their efficacy and low cost (1). The gene discussed is INS; the disease is type 2 diabetes mellitus.